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Patients with gender dysphoria (GD) report signiﬁcant dissociative symptoms and are found to have a high prevalence of a dissociative
disorder of any kind. When GD patients elect to undergo cross-sex hormone therapy, there is a signiﬁcant reduction in dissociative
symptoms. However, to the best of our knowledge, there are no known case reports that describe an alteration of personalities in
dissociative identity disorder after initiating cross-sex hormone therapy. Thus, we present a case of a 20-year-old transgender male
with GD, whom after initiating cross-sex hormone therapy with testosterone experienced an increased presence of his existing
male personalities.

1. Introduction
Gender dysphoria (GD) is deﬁned in the DSM-V as signiﬁcant distress due to an incongruence between one’s experienced or expressed gender and one’s assigned gender. It has
a prevalence ranging from 0.5 to 1.3% in the United States
[1]. Patients with GD report signiﬁcant dissociative symptoms, such as depersonalization/derealization, absorption/imaginativeness, and conversion [2]. Thus, patients with GD
have a high prevalence of a dissociative disorder of any kind
(29.6%) [3]. When GD patients elect to undergo cross-sex
hormone therapy, there is a signiﬁcant reduction in dissociative symptoms [4]. However, to the best of our knowledge,
there are no case reports that describe an alteration of personalities in dissociative identity disorder after initiating
cross-sex hormone therapy. Thus, we present a case of a
20-year-old transgender male with GD, whom after initiating
cross-sex hormone therapy with testosterone, experienced an
increased presence of his existing male personalities.

2. Case
A 20-year-old transgender male with GD, undergoing crosssex hormone therapy with testosterone, with past psychiatric
history of dissociative identity disorder (DID), PTSD, and

depression, was admitted to our inpatient psychiatric hospital after endorsing suicidal ideations and homicidal ideations
towards others. This is context to signiﬁcant distress from
recently switching to one of his personalities. Family history
was positive for depression in his mother and sister. Labs
were unremarkable, except for elevated hemoglobin
(16.7 g/dL), elevated hematocrit (48.7%), and elevated RBC
count (6.12 M/μL). Urine drug screen was positive for
cocaine, amphetamine, and benzodiazepine. The patient did
not recall use of these substances, citing they were done as
his most recent personality, Dexter.
The patient has a history of sexual abuse by his mother’s
boyfriend from when he was 3 years old. He was subsequently diagnosed with PTSD and depression in his early
adolescence. Although he no longer endorsed having nightmares, he continued to have intrusive-type symptoms of
PTSD and a negative emotional state of anger and fear. While
he was seeking outpatient therapy for PTSD and depression,
his therapist diagnosed him with DID. Although he was born
as the female sex, he identiﬁed having 6 personalities, most of
whom are the male gender.
The patient started testosterone therapy two years prior
to presentation, which has alleviated his GD symptoms.
However, since starting testosterone, he noticed an increased
presence of two existing personalities, both of whom are
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male: (1) Dexter, a personality who is aggressive and hostile
and has violent thoughts—he uses illicit drugs; and (2) Bad,
a personality who is evil and destructive—he throws furniture when he is angry and even tried to assault his girlfriend.

3. Discussion
DID, formerly known as multiple personality disorder, falls
under the category of dissociative disorders in the DSM-V,
alongside dissociative amnesia, depersonalization/derealization disorder, other speciﬁed dissociative disorder, and other
unspeciﬁed dissociative disorder [5]. Dissociative disorders
have a prevalence of 5-10% in the general population [6].
The hallmark of dissociative disorders is “an interruption
and/or discontinuity in the normal integration of consciousness, memory, self-identity and subjective identity, emotion,
perception, body identity, motor control and behavior” [6].
There are various factors that may confound or exacerbate
symptoms of dissociative disorders, such as drugs of abuse,
comorbid diagnoses with dissociative features, such as PTSD,
and utilization of hormone therapy.
3.1. Drugs of Abuse and Dissociation. Drugs of abuse have
been known to induce symptoms of dissociation that resemble dissociative disorders. Although the patient denied consistent drug use, his UDS was positive for cocaine,
amphetamine, and benzodiazepine. A study by Kloet D
et al. revealed that participants who were administered cannabis (THC 300 μg/kg), MDMA (single doses of 25, 50 or
100 mg), or cocaine (HCl 300 mg) all had a signiﬁcant
increase in dissociative symptoms compared to placebo, as
measured by the Clinician-Administered Dissociative States
Scale (CADSS) [7]. Speciﬁcally, the most profound eﬀects
were found with cannabis and MDMA; the eﬀect of MDMA
on dissociative symptoms was dose-dependent [7]. Similar to
cocaine, stimulants such as dexamphetamine and methylphenidate can also increase rates of dissociation and psychedelic state [8]. Benzodiazepines are used with caution in
patients with dissociative disorders due to its potential to
exacerbate symptoms of dissociation [9].
3.2. sPTSD and Dissociation. There is considerable overlap
between DID and PTSD. They share a common risk factor
of childhood trauma. The DSM-5 added a dissociative subtype to PTSD to capture patients with PTSD with a predominance of depersonalization/derealization symptoms and
emotional detachment [5]. The prevalence of those with
PTSD dissociative type and any type of dissociative disorder
was as high as 54% [10]. Research has established a diﬀerence
in physiologic and neural response to traumatic memories
between dissociative type PTSD and those with nondissociative PTSD [11]. However, distinguishing between PTSD dissociative subtype and dissociative disorders relies on a
structured clinical interview.
3.3. Testosterone and Dissociation. The psychiatric eﬀects of
androgens on mood are well-studied. Androgens are known
to be associated with an increase in euphoria and energy
but also irritability, violence, and hostility [12]. Speciﬁcally,
testosterone acts in the subcortical structures of the hypo-
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thalamus and amygdala, where aggression and emotions are
localized. The prefrontal cortex interprets and regulates
aggression and emotions. High levels of testosterone downregulate the prefrontal cortex, resulting in an increased
expression of aggression [13]. However, a research gap
remains regarding eﬀects of testosterone on dissociative
symptoms and recollection of traumatic events. It is possible
that initiating testosterone altered his experience of trauma
recollection. In other words, perhaps, the patient’s more masculine alters are a reﬂection of increased testosterone in
patient’s utilization of dissociation to manage traumatic
recollections/events. This would be relevant because
LGBTQ-based discrimination increases overall traumatization which has relevant implications in exacerbation of dissociation and its lasting impacts [14]. This becomes especially
pertinent for this patient as those with worse emotional dysregulation are associated with more severe dissociation phenomena [15].
3.4. Treatment Recommendations. Treatment recommendation for DID is intensive individual psychotherapy that
focuses on recognizing and encouraging the cooperation
between personalities and adapting new coping skills [6].
Although there is not one psychotherapy modality that is recommended, psychodynamic psychotherapy and hypnotic
interventions have been frequently used [6]. We recommended that the patient continues psychotherapy with his
outpatient therapist, whom he was seeing regularly and had
built rapport with. Comorbid diagnoses should be addressed
and treated to reduce risk of suicidality. The patient’s comorbid diagnoses of PTSD and depression were treated with venlafaxine after failing two previous trials of SSRIs. Venlafaxine
was titrated to 225 mg daily. Substance use rehab was oﬀered
to the patient; however, he declined, citing he does not use
substances consistently.

4. Conclusion
In summary, the present case reveals a correlation of testosterone therapy with dissociative symptoms. Although the
patient reported a reduction in distress of his physical body
after initiation of testosterone therapy, he reported an
increase in hostility and violence, as well as an increased predominance of existing male alters. One cannot rule out the
possibility of confounding factors that may have exacerbated
or altered the patient’s dissociative symptoms, such as substance use and clinical overlap of PTSD. Yet, there still exists
a scarcity of literature that describes the eﬀects of testosterone on dissociative symptoms. Areas of further research
may focus on eﬀects of testosterone on the severity of dissociative symptoms, the frequency of switching personalities,
and changes to the alters. Similarly, the eﬀects of other neurochemical compounds, such as estrogen, on dissociative
symptoms are another area of potential research.
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